Koru Medical (KRMD) Q1 2026 Earnings Transcript

KORU Medical reported record quarterly revenue of $11.8 million, up 22% year over year, with domestic core growth of 12%, international core growth of 35%, and PST revenue up 166%. Gross margin slipped 130 bps to 61.5% due to higher production costs and tariffs, but adjusted EBITDA improved 95% to nearly breakeven at negative $10,000 and the company reaffirmed 2026 guidance for $47.5 million-$50 million in revenue, 61%-63% gross margin, and positive EBITDA/cash flow. Management also highlighted progress in the non-Ig pipeline, including a 510(k) filing for deferoxamine, Phase III advances in two collaborations, and upcoming next-generation platform submissions, while warning of geopolitical caution in the Middle East distributor channel.

Analysis

KRMD is transitioning from a single-product compounding story into a platform monetization story, and that matters because it changes the valuation regime: recurring base business can justify a lower cost of capital, while pipeline optionality can start to be assigned as real probability-weighted revenue rather than “free” narrative premium. The key second-order effect is that each new drug label or geography adds not just near-term sales, but also lowers customer acquisition friction for the next asset by increasing installed-device utility and credibility with pharma partners. That can create a self-reinforcing loop where the commercial value of the pump platform rises faster than reported revenue.

The market is likely underappreciating how lumpy international growth can mask underlying adoption strength. Distributor-led prefill launches can pull revenue forward in one quarter and then look soft for a quarter or two before end-user consumables catch up; that makes headline deceleration risk more about timing than demand destruction. The flip side is that if Q2 merely confirms the same pattern the company described, the stock can re-rate on the back half inflection rather than on the beat itself.

The main bear case is execution risk in the handoff from legacy SCIg to broader non-Ig and oncology use cases. A delay in regulatory clearance, slower-than-expected ambulatory clinic adoption, or a weaker-than-expected international reimbursement rollout would compress the narrative quickly because the street is already looking beyond the base business for growth acceleration. A more subtle risk is mix: PST revenue is volatile and can flatter margins temporarily, so investors may overestimate normalized earnings power if pipeline orders do not convert into repeat commercial demand.

Contrarianly, the guide may be more conservative than it looks. Management is effectively embedding geopolitical and launch-timing conservatism while the core business is already near cash breakeven, so any cleaner-than-feared Q2/Q3 execution could force estimate revisions higher. The next catalyst cluster is regulatory, not financial: if Phesgo or Freedom360 filings progress on schedule over the next 1-2 quarters, the market can start capitalizing 2027-2028 earnings, not just 2026 guidance.

Key Decisions for Investors

• Long KRMD on a 3-6 month horizon into the expected Q2/Q3 international pull-through; risk/reward is attractive if the market is underpricing the delayed consumables ramp after distributor orders. Use a tight stop if Europe fails to convert by the next quarter.
• Buy KRMD call spreads 3-6 months out to express upside on regulatory/newsflow asymmetry while limiting downside if guidance stays conservative; best entry is after any post-earnings digestion weakness.
• Pair trade: long KRMD / short a slower-growth medtech with similar multiple but weaker top-line inflection, to isolate execution-driven re-rating from broader multiple compression.
• If KRMD rallies sharply on pipeline headlines alone, fade part of the move unless there is evidence of repeat commercial pull-through; PST and early-stage label additions are not yet the same as durable recurring revenue.
• Watch for a revisit after the next regulatory milestone; if Freedom360 or Phesgo advances on schedule, add exposure ahead of the market’s eventual willingness to capitalize 2027 revenue.